Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.76 |
| ▸ | CCND1 | P24385 | 4/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11366447 | 0.87 | CDK4 (1.00) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL16244758 | 0.80 | CDK4 (0.78) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL29379363 | 0.79 | CDK4 (0.76) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL1120445 | 0.79 | CDK4 (0.76) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL29379265 | 0.79 | CDK4 (0.76) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL3330892 | 0.79 | CDK4 (0.76) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL11624661 | 0.79 | CDK4 (0.76) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL3347874 | 0.79 | CDK4 (0.76) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL734246 | 0.79 | CDK4 (0.76) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL17822342 | 0.79 | CDK4 (0.76) | CDK4CCND1LMNAHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114423742-A | Benzotriazole compound, light absorber, and resin composition | 三井化学株式会社 | 2022-04-29 | — | — | CN | disclosed |
| US-20100076084-A1 | Method of Treating Metabolic Disorders, Especially Diabetes, or a Disease or Condition Associated with Diabetes | GATLIN MARJORIE REGAN | 2010-03-25 | — | — | US | disclosed |
| EP-2011507-A2 | Pharmaceutical composition of nateglinide and another antidiabetic agent | Novartis AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-7361679-B2 | 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2008-04-22 | — | — | US | disclosed |
| US-7335673-B2 | 2,3-Diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2008-02-26 | — | — | US | disclosed |
| US-20070275928-A1 | METHOD OF TREATING METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETES | GATLIN MARJORIE R | 2007-11-29 | — | — | US | disclosed |
| US-20050124663-A1 | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes | GATLIN MARJORIE R (US) | 2005-06-09 | — | — | US | disclosed |
| US-6878749-B2 | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| US-20040259908-A1 | 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1426360-A1 | 2-PHENYL-3-HETEROARYLPROPIONIC ACID DERIVATIVE OR SALT THEREOF AND MEDICINE CONTAINING THE SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2004-06-09 | — | — | EP | disclosed |
| US-20040072878-A1 | 2,3-Diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| US-20030162816-A1 | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes | GATLIN MARJORIE REGAN (US) | 2003-08-28 | — | — | US | disclosed |
| EP-1325903-A1 | 2,3-DIPHENYLPROPIONIC ACID DERIVATIVES OR THEIR SALTS, MEDICINES OR CELL ADHESION INHIBITORS CONTAINING THE SAME, AND THEIR USAGE | Kaken Pharmaceutical Co., Ltd. (JP) | 2003-07-09 | — | — | EP | disclosed |
| US-6559188-B1 | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes | NOVARTIS AG (CH) | 2003-05-06 | — | — | US | disclosed |
| EP-1212077-A2 | PHARMACEUTICAL COMPOSITION OF NATEGLINIDE AND ANOTHER ANTIDIABETIC AGENT | Novartis AG (CH) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001021159-A2 | PHARMACEUTICAL COMPOSITION OF NATEGLINIDE AND ANOTHER ANTIDIABETCAGENT | NOVARTIS AG (CH) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259908-A1 | 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same | LPAR4, LPAR2, LPAR1 | CDK4 2511/4885CCND1 4565/4885LMNA 774/4885 |
| US-20050124663-A1 | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes | SLC2A2, TREH, GOT2 | CDK4 1891/4885CCND1 1394/4885LMNA 1076/4885 |
| US-20100076084-A1 | Method of Treating Metabolic Disorders, Especially Diabetes, or a Disease or Condition Associated with Diabetes | SLC2A2, TREH, GOT2 | CDK4 1891/4885CCND1 1394/4885LMNA 1076/4885 |
| US-20070275928-A1 | METHOD OF TREATING METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETES | SLC2A2, TREH, GOT2 | CDK4 1891/4885CCND1 1394/4885LMNA 1076/4885 |
| US-20040072878-A1 | 2,3-Diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage | VCAM1, ICAM1, PTK2 | CDK4 2961/4885CCND1 4054/4885LMNA 2733/4885 |
| US-20030162816-A1 | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes | SLC2A2, SLC2A1, PPARD | CDK4 1874/4885CCND1 1053/4885LMNA 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.